SAB BIOTHERAPEUTICS, INC. Equity Securities, FV-NI, Realized Gain (Loss)
SAB BIOTHERAPEUTICS, INC. (SABS) reported Equity Securities, FV-NI, Realized Gain (Loss) of $7.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-06-30 was $7.00K, a 46.15% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-03-31 was $2.55K.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-12-31 was $988.00.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-09-30 was $62.83K, a 62.56% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was $39.69K, a 44.14% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was $27.54K.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 12 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.00K 10-Q · filed 2026-08-06 | $3.00K 10-Q · filed 2026-08-06 | $10.54K derived: sum of 3 quarters · filed 2026-08-06 | $73.37K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.55K 10-Q · filed 2026-05-12 | $3.54K derived: sum of 2 quarters · filed 2026-05-12 | $66.37K derived: sum of 3 quarters · filed 2026-05-12 | $79.37K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $988.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $63.82K derived: sum of 2 quarters · filed 2026-03-09 | $76.82K derived: sum of 3 quarters · filed 2026-08-06 | $39.69K 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $62.83K 10-Q · filed 2025-11-14 | $75.83K derived: sum of 2 quarters · filed 2026-08-06 | $38.71K 10-Q · filed 2025-11-14 | $42.62K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $13.00K 10-Q · filed 2026-08-06 | $13.46K 10-Q · filed 2025-08-07 | $25.00K 10-Q · filed 2026-08-06 | $25.33K 10-Q · filed 2025-08-07 | -$20.21K derived: sum of 3 quarters · filed 2026-08-06 | $18.44K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$6.93K 10-Q · filed 2026-05-12 | -$33.22K derived: sum of 2 quarters · filed 2026-05-12 | $5.44K derived: sum of 3 quarters · filed 2026-05-12 | $5.44K derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$26.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $12.37K derived: sum of 2 quarters · filed 2026-03-09 | $12.37K derived: sum of 3 quarters · filed 2026-03-09 | $27.54K 10-K · filed 2026-03-09 | $0.00 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $38.65K 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2024-11-06 | $38.65K derived: sum of 2 quarters · filed 2025-11-14 | $53.82K 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |